PTO/SB/05 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1 53(h))

Attorney Docket No.	1975.0180003/TJS
First Inventor	UMAÑA et al.
Title	FUSION CONSTRUCTS AND USE OF SAME TO PRODUCE ANTIBODIES WITH INCREASED FC RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION
Everess Mail Lahel No	

(100)			Express Mail Labe	31 100.										
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.			Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450											
(Submit au 2. Applican See 37 (3. Specifica (preferred - Descript - Cross R - Stateme - Referen or a com - Backgro - Brief Su - Brief De - Detailed - Claim(s) - Abstract	n original and a dit claims small CFR 1.27. ation arrangement set it we title of the inveference to Relate the Regarding Fe ce to sequence I uputer program li und of the Invenmary of the Invescription of the CI Description	[Total Pages 165] If forth below) It forth below be	B. Nucleotide ar (if applicable, a. X Col b. Sp i. ii. X c. X Sta	all necessary) mputer Readable F ecification Sequence CD-ROM or CD- Paper atements verifying i	equence Submission orm (CRF) ce Listing on: -R (2 copies); or dentity of above copie PLICATION PAR r sheet & document(s	TS :))								
5. Oath or Declaration a. Newly executed (original or copy) b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 18 completed) i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) name in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 6. X Application Data Sheet. See 37 CFR 1.76			(when there is an assignee) Attorney English Translation Document (if applicable) Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations Preliminary Amendment Acture Receipt Postcard (MPEP 503) (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Other: Authorization under 37CFR 1.136(a)(3) The name of the assignee is: GlycArt Biotechnology AG											
							18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the title, or in an Application Data Sheet under 37 CFR 1.76:							
							Continuation Divisional Continuation-in-part (CIP) of prior application No.:							
							Prior application information: Examiner For CONTINUATION OF DIVISIONAL APPS only; The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.							
19. CORRESPONDENCE ADDRESS														
X Customer Number: 26111			OR Correspondence address below											
Name Sterne, Kessler, Goldstein & Fox P.L.L.C.														
Address														
City			State		Zip Code									
Country		To	elephone		Fax									
Name (Print/Type) Timothy I Shept Jr. Registration No. (Attorney/Agent) 41,306														
Signature	1 /m	willy Suf.			Date 01/22/	04								

This collection of information is required by 37 CFR 1.53(b) The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

UMAÑA et al.

Appl. No.: To be Assigned

Filed: January 22, 2004

For: Fusion Constructs and Use of Same

to Produce Antibodies With Increased Fc Receptor Binding Affinity and Effector Function Confirmation No.: To be Assigned

Art Unit: To be Assigned Examiner: To be Assigned

Atty. Docket: 1975.0180003/TJS

Authorization to Treat a Reply as Incorporating an Extension of Time Under 37 C.F.R. § 1.136(a)(3)

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Timothy J/Shea, Jr.

Attorney for Applicants Registration No. 41,306

Date: <u>January 22, 2004</u>

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600 222213_1.DOC



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michaele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee CIC K. Stelle Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Michael V. Messinger

Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Heidi L. Kraus Edward W. Yee Albert L. Ferro* Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Kimberly N. Reddick

Theodore A. Wood Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rae Lynn Prengaman Jane Shershenovich* Lawrence J. Carroll* George S. Bardmesser Daniel A. Klein* Jason D. Eisenberg lason D. Fisenberg Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller* Jon E. Wright* LuAnne M. Yuricek* John J. Figueroa

Ann E. Summerfield Tiera S. Coston* Aric W. Ledford*

Registered Patent Agents • Nancy J. Leith Helene C. Carlson Gaby L. Longsworth Matthew J. Dowd Aaron L. Schwartz Mary B. Tung Katrina Y. Pei Quach Bryan L. Skelton Robert A. Schwartzman Timothy A. Doyle Jennifer R. Mahalingappa

Mail Stop Patent Application

Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Eric D. Hayes

<u>Of Counsel</u> Kenneth C. Bass III Evan R. Smith

*Admitted only in Maryland * Admitted only in Virginia • Practice Limited to Federal Agencies

January 22, 2004

WRITER'S DIRECT NUMBER: (202) 772-8679 INTERNET ADDRESS: TSHEA@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Non-Provisional Utility Patent Application under 37 C.F.R. § 1.53(b)

Appl. No. To be Assigned; Filed: January 22, 2004

Fusion Constructs and Use of Same to Produce Antibodies With **Increased Fc Receptor Binding Affinity and Effector Function**

Inventors: Our Ref:

UMAÑA et al. 1975.0180003/TJS

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

- USPTO Utility Patent Application Transmittal Form PTO/SB/05;
- 37 C.F.R. § 1.136(a)(3) Authorization to Treat a Reply As Incorporating 2. An Extension of Time;
- 3. U.S. Utility Patent Application entitled:

Fusion Constructs and Use of Same to Produce Antibodies With Increased Fc Receptor Binding Affinity and Effector Function

and naming as inventors:

Pablo Umaña Peter Bruenker Claudia Ferrara **Tobias Suter**

the application comprising:

an Application Data Sheet (37 C.F.R. § 1.76); a.

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents January 22, 2004 Page 2

- b. specification containing:
 - i. one hundred twenty-nine pages of description prior to the claims;
 - ii. thirty-five pages of claims (286 claims);
 - iii. a one (1) page abstract;
- c. forty-three sheets of drawings: (Figures 1-6, 7A-7B, 8A-8B, 9-13, 14A-14B, 15-16, 17A-17B, 18-21, 22A-22B, 23-26, 27A-27B, 28A-28B, 29-31, 32A-32C, 33A-33B, 34, 35A-35B, 36-37);
- d. twenty-one pages of a paper copy of the sequence listing; and
- e. A computer readable disk copy of the sequence listing.
- 4. Two (2) return postcards.

In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith are the same.

The name of the assignee is GlycArt Biotechnology AG.

Correspondence should be sent to Customer Number 26111.

It is respectfully requested that, of the two attached postcards, one be stamped with the filing date of these documents and returned to our courier, and the other, prepaid postcard, be stamped with the filing date and unofficial application number and returned as soon as possible.

This patent application is being submitted under 37 C.F.R. § 1.53(b) without Declaration and without filing fee.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Timothy J. Shea, Jr.

Attorney for Applicants

Registration No. 41,306

TJS/slw Enclosures

222128_1.DOC